Table 2

IOP elevation and management in the IRISS study population post-FAc implant administration

IRISS
(n=593)
IOP events
IOP post-FAc, n (%)
 >21 mm Hg199 (33.6)
 >25 mm Hg113 (19.1)
 >30 mm Hg49 (8.3)
CDR, mean±SD0.46±0.195*
IOP treatments
Trabeculoplasty, n (%)2 (0.3)
Trabeculectomy, n (%)7 (1.2)
Incisional IOP-lowering surgery, n (%)5 (0.8)
No of treatment-emergent IOP-lowering medications†, n (%)
 Any138 (23.3)
 162 (44.9)
 230 (21.7)
 321 (15.2)
 >325 (18.2)
Time to first IOP-lowering medication post-FAc‡, days, mean±SD244.2±197.9
  • *Month 24 CDR data are available for 32 patients.

  • †IOP-lowering medication initiated after 0.2 µg/day FAc implant administration.

  • ‡Data were available for 138 patients (23.3% of the study population).

  • CDR, cup:disc ratio; FAc, fluocinolone Acetonide; IOP, intraocular pressure; IRISS, ILUVIEN Registry Safety Study.